Agenus Inc. (AGEN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Agenus Inc. (AGEN) Healthcare & Pipeline Overview

Agenus Inc. is a clinical-stage biotechnology company specializing in immuno-oncology, leveraging its Retrocyte Display platform and Stimulon adjuvant to develop novel antibodies and vaccine programs. With a focus on solid tumors and hematological malignancies, Agenus collaborates with industry leaders to advance its pipeline of therapeutic candidates.

What Is the Investment Thesis for AGEN?

Agenus Inc. presents a notable research candidate within the immuno-oncology sector, driven by its diverse pipeline of clinical-stage assets and proprietary technology platforms. The company's Retrocyte Display platform and QS-21 Stimulon adjuvant provide a foundation for developing novel antibodies and vaccine programs. Key value drivers include the advancement of Balstilimab, an anti-PD-1 antagonist, through clinical trials and potential regulatory approval. Furthermore, the development of AGEN1181, an anti-CTLA-4 monospecific antibody, and other pipeline assets targeting various cancers could unlock significant value. The company's collaborations with industry leaders like Incyte and Merck further validate its technology and provide potential revenue streams. However, investors should be aware of the risks associated with clinical-stage biotechnology companies, including clinical trial failures, regulatory hurdles, and competition from established players.

Based on FMP financials and quantitative analysis

AGEN Key Highlights

Agenus Inc. operates with a market capitalization of $287M, reflecting its position as a clinical-stage biotechnology company.

• The company's P/E ratio stands at 2.54, indicating investor expectations of future earnings growth.
• Agenus Inc. maintains a profit margin of 0.1%, highlighting the challenges of profitability in the biotechnology sector.
• The company's gross margin is 35.7%, reflecting the cost of goods and services relative to revenue.
• Agenus Inc. has a beta of 1.67, suggesting higher volatility compared to the overall market.

Who Are AGEN's Competitors?

AGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AGEN's Key Strengths?

Proprietary technology platforms for antibody and vaccine development.

• Diverse pipeline of clinical-stage immuno-oncology assets.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in immuno-oncology.

What Are AGEN's Weaknesses?

Reliance on clinical trial success for product development.

• Limited financial resources compared to larger pharmaceutical companies.
• Dependence on collaborations for revenue generation.
• High risk of clinical trial failures and regulatory setbacks.

What Could Drive AGEN Stock Higher?

Clinical trial results for AGEN1181, an anti-CTLA-4 monospecific antibody, in Phase 1/2 clinical trials.

• Regulatory submission and potential approval of Balstilimab for second-line cervical cancer.
• Expansion of collaborations with pharmaceutical companies to develop and commercialize Agenus's pipeline assets.
• Advancement of AGEN2373, an anti-CD137 monospecific antibody, through Phase 1 clinical trials.
• Progress in the development of AGEN1777, an anti-TIGIT bispecific antibodies.

What Are the Key Risks for AGEN?

Financial-distress signal — its Altman Z-Score of -14.34 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-23.1%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures for key pipeline assets.
• Regulatory setbacks and delays in product approvals.
• Competition from established pharmaceutical companies with larger resources.
• Patent expirations and generic competition.
• Dependence on collaborations for revenue generation.

What Are the Growth Opportunities for AGEN?

• Advancement of Balstilimab: Balstilimab, an anti-PD-1 antagonist, represents a significant growth opportunity for Agenus. Having completed Phase II clinical trials for second-line cervical cancer, potential regulatory approval and commercialization could generate substantial revenue. The market for PD-1 inhibitors is projected to reach $40 billion by 2027. Agenus aims to secure partnerships for broader indications, expanding the market reach and revenue potential for Balstilimab.
• Development of AGEN1181: AGEN1181, an anti-CTLA-4 monospecific antibody, is currently in Phase 1/2 clinical trials. CTLA-4 inhibitors have demonstrated efficacy in various cancers, and AGEN1181's unique properties could offer improved therapeutic outcomes. The CTLA-4 inhibitor market is expected to grow to $5 billion by 2028. Successful clinical trials and subsequent commercialization of AGEN1181 could significantly contribute to Agenus's revenue growth.
• Expansion of QS-21 Stimulon Adjuvant: QS-21 Stimulon adjuvant is a key component of Agenus's vaccine programs and has the potential to enhance the efficacy of various vaccines. The global vaccine adjuvant market is projected to reach $1.4 billion by 2027. Agenus aims to expand the use of QS-21 in collaborations with other companies, generating revenue through licensing agreements and supply contracts.
• Strategic Collaborations: Agenus has established collaborations with companies like Incyte, Merck, and Gilead, providing access to resources and expertise. These collaborations can accelerate the development and commercialization of Agenus's pipeline assets. Future strategic partnerships could further expand Agenus's reach and revenue potential. The market for immuno-oncology collaborations is expected to grow as companies seek to leverage external innovation.
• Proprietary Technology Platforms: Agenus's Retrocyte Display platform and other proprietary technologies provide a competitive advantage in the discovery and development of novel antibodies and vaccine programs. These platforms enable Agenus to identify and optimize therapeutic candidates more efficiently. The market for antibody discovery platforms is projected to grow as companies seek to develop innovative biologics.

What Are AGEN's Competitive Advantages?

• Proprietary Retrocyte Display platform for antibody discovery.
• QS-21 Stimulon adjuvant for enhancing vaccine efficacy.
• Extensive pipeline of clinical-stage immuno-oncology assets.
• Strategic collaborations with leading pharmaceutical companies.

What Does AGEN Do?

Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. is an immuno-oncology company dedicated to discovering and developing therapies that harness the body's immune system to fight cancer. Originally named Antigenics Inc., the company rebranded to Agenus Inc. in January 2011 to reflect its expanded focus on immuno-oncology. Agenus operates through its proprietary platforms, including Retrocyte Display, an antibody expression platform used to identify fully human and humanized monoclonal antibodies. Its product pipeline includes vaccine programs like the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Agenus is also developing multiple antibody programs, including Balstilimab, an anti-PD-1 antagonist, and AGEN1181, an anti-CTLA-4 monospecific antibody. These therapies target various cancers and are in different stages of clinical trials. Agenus has established collaborations with companies like Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. to further develop and commercialize its immuno-oncology products. The company's mission is to provide innovative treatments for patients with cancer by leveraging its expertise in immuno-oncology and its portfolio of novel therapeutic candidates.

What Products and Services Does AGEN Offer?

• Discovers and develops immuno-oncology products.
• Offers Retrocyte Display, an antibody expression platform.
• Develops vaccine programs, including Prophage and QS-21 Stimulon adjuvant.
• Develops Balstilimab, an anti-PD-1 antagonist.
• Develops AGEN1181, an anti-CTLA-4 monospecific antibody.
• Develops AGEN2373, an anti-CD137 monospecific antibody.
• Develops AGEN1423, an anti-CD73/TGFß TRAP bi-functional antibody.
• Develops AGEN1777, an anti-TIGIT bispecific antibodies.

How Does AGEN Make Money?

• Develops and out-licenses its proprietary technologies and therapeutic candidates.
• Generates revenue through collaborations with pharmaceutical companies.
• Receives milestone payments and royalties from partnered programs.
• Commercializes its own products upon regulatory approval.

What Industry Does AGEN Operate In?

Agenus Inc. operates in the rapidly evolving immuno-oncology sector, which is projected to reach $79.4 billion by 2028, growing at a CAGR of 12.4% from 2021. The competitive landscape includes major pharmaceutical companies like Merck (MRK) and Bristol-Myers Squibb (BMY), as well as specialized biotech firms. Agenus differentiates itself through its proprietary Retrocyte Display platform and QS-21 Stimulon adjuvant, which enable the development of novel antibodies and vaccine programs. The company's focus on solid tumors and hematological malignancies positions it to capitalize on the growing demand for innovative cancer therapies.

Who Are AGEN's Key Customers?

• Pharmaceutical companies seeking to develop immuno-oncology therapies.
• Patients with cancer who may benefit from Agenus's products.
• Research institutions and academic centers.
• Government agencies involved in healthcare and research.

Agenus Inc. (AGEN) Valuation Context

Valued at $287M, AGEN is classified as a micro-cap stock. Analyst price targets span from $25.00 to $25.00, with a consensus of $25.00. At the current price of $6.89, that implies approximately 263% upside potential. Relative to its peer group, AGEN's quantitative score of 25/100 is below the peer average of 74/100.

AGEN Revenue & Earnings Trend

In Jun 2026, AGEN generated $34.5M in top-line revenue, marking a sequential increase of 2.3%. The company recorded a net loss of $550K, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AGEN averaged $0.66 in diluted EPS.

Company Profile

Agenus Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Garo H. Armen. AGEN has traded publicly since 2000.

Return on equity for Agenus Inc. stands at -23.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 34.6%, showing how much profit it generates from its asset base. AGEN trades at a trailing price-to-earnings ratio of 2.54, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -60.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.38 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 48.7%, the inverse of the P/E and a quick read on earnings relative to price.

Agenus Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -14.34 places it in the distress zone, a signal of elevated financial risk.

Agenus Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 8.3% below estimates on average.

Wall Street analysts project Agenus Inc. revenue of about $138.8M for fiscal 2026, with EPS near $0.78.

Over the past six months, Agenus Inc. insiders filed 33 SEC Form 4 transactions — 0 sales and 33 purchases. On net that is roughly 4.8M shares acquired (about $28.4M) — insiders putting money in tends to read as conviction.

AGEN Financials

AGEN Latest News

AGEN Analyst Consensus

AGEN MoonshotScore

What Investors Ask About Agenus Inc. (AGEN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources